JP2007507514A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007507514A5 JP2007507514A5 JP2006534060A JP2006534060A JP2007507514A5 JP 2007507514 A5 JP2007507514 A5 JP 2007507514A5 JP 2006534060 A JP2006534060 A JP 2006534060A JP 2006534060 A JP2006534060 A JP 2006534060A JP 2007507514 A5 JP2007507514 A5 JP 2007507514A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- members
- substituent assignments
- independent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 60
- 125000000217 alkyl group Chemical group 0.000 claims 46
- 229910052799 carbon Inorganic materials 0.000 claims 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 33
- 239000000203 mixture Substances 0.000 claims 33
- -1 -NR a R b Chemical group 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 229910052757 nitrogen Inorganic materials 0.000 claims 22
- 238000000034 method Methods 0.000 claims 19
- 206010061218 Inflammation Diseases 0.000 claims 17
- 230000004054 inflammatory process Effects 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 230000004044 response Effects 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000002148 esters Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 7
- 238000006243 chemical reaction Methods 0.000 claims 7
- 239000003377 acid catalyst Substances 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 238000003379 elimination reaction Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000012429 reaction media Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 2
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical group [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 claims 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047112 Vasculitides Diseases 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000009285 allergic inflammation Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 claims 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 150000004050 homopiperazines Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 229910052747 lanthanoid Inorganic materials 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 claims 1
- 239000011968 lewis acid catalyst Substances 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 150000004885 piperazines Chemical class 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- HZXJVDYQRYYYOR-UHFFFAOYSA-K scandium(iii) trifluoromethanesulfonate Chemical compound [Sc+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HZXJVDYQRYYYOR-UHFFFAOYSA-K 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 claims 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50717603P | 2003-09-30 | 2003-09-30 | |
| PCT/US2004/032003 WO2005033088A1 (en) | 2003-09-30 | 2004-09-29 | Quinoxaline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007507514A JP2007507514A (ja) | 2007-03-29 |
| JP2007507514A5 true JP2007507514A5 (OSRAM) | 2007-11-22 |
Family
ID=34421591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534060A Pending JP2007507514A (ja) | 2003-09-30 | 2004-09-29 | キノキサリン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050070527A1 (OSRAM) |
| EP (1) | EP1670774A1 (OSRAM) |
| JP (1) | JP2007507514A (OSRAM) |
| KR (1) | KR20060111466A (OSRAM) |
| CN (1) | CN1886389B (OSRAM) |
| AU (2) | AU2004278372B2 (OSRAM) |
| CA (1) | CA2540638A1 (OSRAM) |
| IL (1) | IL174629A0 (OSRAM) |
| MX (1) | MXPA06003578A (OSRAM) |
| WO (1) | WO2005033088A1 (OSRAM) |
| ZA (1) | ZA200603410B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| JP5066175B2 (ja) | 2006-03-31 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン |
| US20090069343A1 (en) * | 2006-04-10 | 2009-03-12 | Dunford Paul J | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus |
| US20100016293A1 (en) * | 2006-07-03 | 2010-01-21 | Rogier Adriaan Smits | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use |
| GB0614471D0 (en) | 2006-07-20 | 2006-08-30 | Syngenta Ltd | Herbicidal Compounds |
| US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| EP2077263A1 (en) * | 2008-01-02 | 2009-07-08 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Quinazolines and related heterocyclic compounds and their therapeutic use |
| NZ603072A (en) * | 2008-06-12 | 2013-01-25 | Janssen Pharmaceutica Nv | Use of histamine H4 antagonist for the treatment of post-operative tissue adhesions after surgical procedures |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| EP2201982A1 (en) | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| EA201491990A1 (ru) | 2012-05-03 | 2015-02-27 | Новартис Аг | L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов |
| ES2683380T3 (es) | 2012-06-08 | 2018-09-26 | Sensorion | Inhibidores del receptor H4 para tratar el tinnitus |
| EA201591648A1 (ru) | 2013-03-06 | 2016-02-29 | Янссен Фармацевтика Нв | Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4 |
| CN105001169B (zh) * | 2015-07-09 | 2017-07-21 | 华侨大学 | 一种3‑氨基喹喔啉‑2(1h)‑酮类化合物的合成方法 |
| CN110092760B (zh) * | 2019-06-04 | 2020-11-13 | 杭州师范大学 | 一种3-氟代烷氧基-2(1h)-喹喔啉酮及其合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3493572A (en) * | 1968-07-05 | 1970-02-03 | Pfizer & Co C | Process for producing quinoxaline-di-n-oxides |
| FI193974A7 (OSRAM) * | 1973-07-13 | 1975-01-14 | Merck & Co Inc | |
| EP0008864A1 (en) * | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| DK716188D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
| DE4342024A1 (de) * | 1993-12-09 | 1995-06-14 | Hoechst Ag | Kombinationspräparate, enthaltend ein Chinoxalin und ein Nukleosid |
| MY132385A (en) * | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
| KR20050025628A (ko) * | 2002-07-19 | 2005-03-14 | 바이오비트럼 에이비 | 5-ｈｔ2ａ 수용체 관련 장애의 치료를 위한 신규피페라지닐-피라지논 유도체 |
-
2004
- 2004-09-29 EP EP04789260A patent/EP1670774A1/en not_active Withdrawn
- 2004-09-29 WO PCT/US2004/032003 patent/WO2005033088A1/en not_active Ceased
- 2004-09-29 KR KR1020067008422A patent/KR20060111466A/ko not_active Withdrawn
- 2004-09-29 AU AU2004278372A patent/AU2004278372B2/en not_active Ceased
- 2004-09-29 US US10/953,126 patent/US20050070527A1/en not_active Abandoned
- 2004-09-29 CN CN2004800348033A patent/CN1886389B/zh not_active Expired - Fee Related
- 2004-09-29 JP JP2006534060A patent/JP2007507514A/ja active Pending
- 2004-09-29 MX MXPA06003578A patent/MXPA06003578A/es unknown
- 2004-09-29 CA CA002540638A patent/CA2540638A1/en not_active Abandoned
-
2006
- 2006-03-29 IL IL174629A patent/IL174629A0/en unknown
- 2006-04-28 ZA ZA200603410A patent/ZA200603410B/en unknown
-
2010
- 2010-05-18 AU AU2010202009A patent/AU2010202009A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007507514A5 (OSRAM) | ||
| CN1129581C (zh) | 氰基苯基衍生物 | |
| ES2549087T3 (es) | Derivados de aminodihidrotiazina como inhibidores de BACE para el tratamiento de la enfermedad de Alzheimer | |
| DE69110320T2 (de) | Stickstoff enthaltende heterozyklische Verbindungen, ihre Herstellung und Verwendung. | |
| JP4853965B2 (ja) | アダマンタン誘導体およびアザビシクロオクタン誘導体およびアザビシクロノナン誘導体、ならびにこれらの調製方法およびｄｐｐ−ｉｖ阻害剤としてのこれらの使用 | |
| CA2657702A1 (en) | Quinazolines and related heterocyclic comp0unds, and their therapeutic use | |
| JPS61152662A (ja) | 新規な二環式複素アリールピペラジン化合物とその医薬並びにその製造法 | |
| KR101580700B1 (ko) | ５-［（３,３,３-트리플루오로-２-히드록시-１-아릴프로필）아미노］-１ｈ-퀴놀린-２-온, 그의 제조 방법, 및 항염증제로서 그의 용도 | |
| HU220041B (hu) | Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények | |
| ATE1899T1 (de) | Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen. | |
| KR20160111999A (ko) | 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제 | |
| WO2004007471A1 (ja) | Ｎ−フェニル−（２ｒ，５ｓ）ジメチルピペラジン誘導体 | |
| WO2006125180B1 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| MX2009000110A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor grp38. | |
| ZA200604395B (en) | Novel M3 Muscarinic Acetylcholine receptor antagonists | |
| JP2007524706A (ja) | ピペリジニルアルキルカーバメートの誘導体、これらの製造方法及びｆａａｈ酵素インヒビターとしての使用 | |
| AU2006322185A1 (en) | Trisubstituted quinazolinone derivatives as vanilloid antagonists | |
| JP2014504648A5 (OSRAM) | ||
| JPH04182467A (ja) | ジアリールメトキシピペリジン誘導体 | |
| JP7618642B2 (ja) | インターロイキンの調節におけるプロドラッグ | |
| JPS58159480A (ja) | 新規なフエニルピペラジン誘導体 | |
| JP2823620B2 (ja) | ２−ヒドロキシ−３−フェノキシ−プロピル−置換ピペラジンないしはホモピペラジン | |
| RU2015114405A (ru) | Замещенные соединения фенилкарбамата | |
| JPS5840552B2 (ja) | １，４− ベンゾジオキサンノ アミンユウドウタイノセイホウ | |
| JP2008538762A (ja) | 新規ムスカリン受容体アンタゴニスト |